Finally, DOT1L inhibition has also been assessed in NPM1 mutant AML and resulted synergistic with menin–MLL inhibitors in suppressing HOX, MEIS1, and FLT3 gene expression and inducing AML cell differentiation (61). The gene discussed is MEN1; the disease is acute myeloid leukemia.